Ribomic Inc.

The University of Tokyo

Otsuka Pharmaceutical Company, Limited

Fujimoto Pharmaceutical Corporation

Asahi Kogaku Kogyo Kabushiki Kaisha

Mitsubishi Chemical Corporation

Jx Nippon Oil Energy Corporation

Zenyaku Kogyo Kabushiki Kaisha

Cellmid Limited

Yoshikazu Nakamura

Shin Miyakawa

Masatoshi Fujiwara

Takashi Matsui

Sadatoshi Sakuma

Ling Jin

Akira Ishiguro

Akio Suzumura

Hisanao Hiramatsu

Masahiro Muraguchi

Satoko Yamazaki

Jinyan Wang

Kenji Kadomatsu

Kazuhiko Haruta

Shoji Ohuchi

Yosuke Nonaka

Kaori Murata

Maiko Sakamoto

Daisuke Anraku

Hisako Ikeda

Kouichi Inoue

Kenjiro Matsuoka

Takushi Nagashima

Ping Mu

Natsuki Otaki

Yusuf Ali

Kazumasa Akita

The present invention provides an aptamer that binds to chymase, and contains a common sequence represented by UAACRNRGGGG wherein Rand Rare each any one base, and Nshows 3 to 30 bases (uracil is optionally thymine).

Anti-chymase aptamer and use for same

Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.

Aptamer for NGF and use thereof

The present invention provides an aptamer that binds to IL-17 to inhibit binding of IL-17 and IL-17 receptor; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a medicament containing the aptamer, or a complex containing the aptamer and a functional substance, a diagnosing drug and labeling agent and the like.

Aptamer to IL-17 and use thereof

The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): whereinX1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond,X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, andX3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.

Aptamer against midkine and applications thereof

A process for producing a caking additive for coke production, the process including a step of extracting a solvent deasphalted pitch that can be used as a caking additive for coke production from a residue containing at least one of an atmospheric residue obtained by atmospheric distillation of a crude oil and a vacuum residue obtained by atmospheric distillation and vacuum distillation of a crude oil, wherein the extraction is performed using, as a solvent, a light reformate obtained by catalytic reforming a naphtha fraction that is fractionated from a crude oil by atmospheric distillation of the crude oil.

Process for producing caking additive for coke production and process for producing coke

Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2):

Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by XGAUAGANNUAAXwherein Xand Xare the same or different and each is A or G, and Nand Nare the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.

Aptamer for chymase, and use thereof

Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Aptamer to FGF2 and use thereof

The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells

The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.

Nucleic acid capable of binding to immunoglobulin G and use thereof

The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex.

Aptamer against IL-17 and use thereof

Method for treatment or prevention of disease associated with functional disorder of regulatory T cell

Provided is a high-quality aptamer against midkine. An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling agent and the like comprising an aptamer possessing a binding activity or inhibitory activity against midkine, or a complex comprising the aptamer and a functional substance; a cell migration inhibitor, a diagnostic reagent, a labeling agent and the like.

Aptamer against midkine and use thereof

A body structure of a camera having a film cartridge chamber which as a whole is formed in the shape of a hollow cylinder and has an opening/closing lid at an axial end portion thereof. The hollow cylindrical film cartridge chamber is formed by a camera body and a rear cover which is formed separately from the camera body and is secured to a rear of the camera body. The outer appearance of the camera is formed by an outer surface of the rear cover. It is possible to make the camera further compact.

Growing community of inventors

Tokyo, Japan

Yoshikazu Nakamura